These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 12176790)

  • 1. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model.
    Hollender A; Kvaloy S; Nome O; Skovlund E; Lote K; Holte H
    Ann Oncol; 2002 Jul; 13(7):1099-107. PubMed ID: 12176790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
    Boehme V; Zeynalova S; Kloess M; Loeffler M; Kaiser U; Pfreundschuh M; Schmitz N
    Ann Oncol; 2007 Jan; 18(1):149-157. PubMed ID: 17018708
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
    Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
    Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-hodgkin lymphoma.
    Tomita N; Kodama F; Kanamori H; Motomura S; Ishigatsubo Y
    Cancer; 2002 Aug; 95(3):576-80. PubMed ID: 12209750
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
    Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
    J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma.
    Chua SL; Seymour JF; Streater J; Wolf MM; Januszewicz EH; Prince HM
    Leuk Lymphoma; 2002 Sep; 43(9):1783-8. PubMed ID: 12685832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement. A single centre analysis.
    Hollender A; Kvaloy S; Lote K; Nome O; Holte H
    Eur J Cancer; 2000 Sep; 36(14):1762-8. PubMed ID: 10974623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical significance of occult cerebrospinal fluid involvement assessed by flow cytometry in non-Hodgkin's lymphoma patients at high risk of central nervous system disease in the rituximab era.
    Sancho JM; Orfao A; Quijano S; García O; Panizo C; Pérez-Ceballos E; Deben G; Salar A; González-Barca E; Alonso N; García-Vela JA; Capote J; Peñalver FJ; Provencio M; Arias J; Plaza J; Caballero D; Morado M; Feliu E; Ribera JM;
    Eur J Haematol; 2010 Oct; 85(4):321-8. PubMed ID: 20528905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations.
    Tomita N; Kodama F; Sakai R; Koharasawa H; Hattori M; Taguchi J; Fujita H; Tanabe J; Fujisawa S; Fukawa H; Harano H; Kanamori H; Miyashita H; Matsuzaki M; Ogawa K; Motomura S; Maruta A; Ishigatsubo Y
    Leuk Lymphoma; 2000 Jul; 38(3-4):335-43. PubMed ID: 10830740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk factors for central nervous system involvement in non-Hodgkins-lymphoma--a multivariate analysis.
    Keldsen N; Michalski W; Bentzen SM; Hansen KB; Thorling K
    Acta Oncol; 1996; 35(6):703-8. PubMed ID: 8938217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
    Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
    J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma.
    van Besien K; Ha CS; Murphy S; McLaughlin P; Rodriguez A; Amin K; Forman A; Romaguera J; Hagemeister F; Younes A; Bachier C; Sarris A; Sobocinski KS; Cox JD; Cabanillas F
    Blood; 1998 Feb; 91(4):1178-84. PubMed ID: 9454747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
    Bokstein F; Lossos A; Lossos IS; Siegal T
    Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of pediatric non-Hodgkin's lymphoma.
    Blay JY; Louis D; Bouffet E; Thiesse P; Biron P; Favrot MC; Brunat-Mentigny M; Philip T
    Blood Rev; 1991 Jun; 5(2):90-7. PubMed ID: 1912759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intrathecal chemotherapy in lymphomatous meningitis.
    Canova F; Marino D; Trentin C; Soldà C; Ghiotto C; Aversa SM
    Crit Rev Oncol Hematol; 2011 Aug; 79(2):127-34. PubMed ID: 20696592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience.
    Zinzani PL; Magagnoli M; Frezza G; Prologo G; Gherlinzoni F; Bendandi M; Albertini P; Babini L; D'Alessandro R; Tura S
    Leuk Lymphoma; 1999 Feb; 32(5-6):571-6. PubMed ID: 10048430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Central nervous system disease in hematologic malignancies: historical perspective and practical applications.
    Pui CH; Thiel E
    Semin Oncol; 2009 Aug; 36(4 Suppl 2):S2-S16. PubMed ID: 19660680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Secondary involvement of the central nervous system in malignant non-Hodgkin's lymphoma. A study of 30 cases in a series of 498 patients.
    Hoerni-Simon G; Suchaud JP; Eghbali H; Coindre JM; Hoerni B
    Oncology; 1987; 44(2):98-101. PubMed ID: 3574856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma.
    Alvarnas JC; Negrin RS; Horning SJ; Hu WW; Long GD; Schriber JR; Stockerl-Goldstein K; Tierney K; Wong R; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 2000; 6(3A):352-8. PubMed ID: 10905773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CNS involvement in children with newly diagnosed non-Hodgkin's lymphoma.
    Sandlund JT; Murphy SB; Santana VM; Behm F; Jones D; Berard CW; Furman WL; Ribeiro R; Crist WM; Greenwald C; Chen G; Walter A; Pui CH
    J Clin Oncol; 2000 Aug; 18(16):3018-24. PubMed ID: 10944136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.